DrugPatentWatch Database Preview

Helsinn Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for HELSINN HLTHCARE, and when can generic versions of HELSINN HLTHCARE drugs launch?

HELSINN HLTHCARE has four approved drugs.

There are eighteen US patents protecting HELSINN HLTHCARE drugs.

There are one hundred and eighty patent family members on HELSINN HLTHCARE drugs in sixty-three countries and fourteen supplementary protection certificates in ten countries.

Summary for Helsinn Hlthcare

International Patents:	180
US Patents:	18
Tradenames:	2
Ingredients:	3
NDAs:	4

Drugs and US Patents for Helsinn Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	AP	RX	Yes	Yes	8,518,981*PED				Y
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	9,271,975
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003	AP	RX	Yes	Yes	8,729,094*PED				Y
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	AP	RX	Yes	Yes	9,439,854*PED				Y

Expired US Patents for Helsinn Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	CAPSULE;ORAL	022233-001	Aug 22, 2008	5,202,333
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014	5,202,333
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003	5,202,333*PED
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	5,202,333*PED

Non-Orange Book US Patents for Helsinn Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,479,483	4-phenyl-pyridine derivatives
9,308,266	Liquid pharmaceutical formulations of palonosetron

International Patents for Helsinn Hlthcare Drugs

Country	Document Number	Estimated Expiration
Israel	134654
Spain	2494015
Canada	2573363
Georgia, Republic of	P20084445

Supplementary Protection Certificates for Helsinn Hlthcare Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2015	Austria		PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20150527
2015 00044	Denmark		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150527
2015036,C1035115	Lithuania		PRODUCT NAME: NETUPITANTAS; REGISTRATION NO/DATE: EU/1/15/1001 20150527
C0049	France		PRODUCT NAME: NETUPITANT OU L'UN DE SES SELS D'ADDITION D'ACIDES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1001 20150529

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Helsinn Hlthcare